Strategy

To deliver transformative Antibody Drug Conjugate (ADC) medicines to patients with unmet medical needs.

Develop precision linkers to enable the best ADC design.

Lead ADC innovation by identifying novel payloads and best payload combinations in dual-payload-ADC.

About Us

Revolutionizing Antibody Drug Conjugates With Precision and Innovation

Baylink Biosciences is transforming cancer treatment by developing next-generation antibody-drug conjugates powered by breakthrough linker technology that enables innovative payloads.

Technology

Revolutionizing ADCs with precision and innovation

Breakthrough
Linker Technology

Baylink's novel linkers expand payload diversity, enabling use of hydrophobic drugs.

Unique design features are incorporated in the linker technology to reduce off-target effects and improve payload delivery to tumors.

Innovative
Payloads

Baylink is developing innovative payloads beyond TOP1i and MMAE payloads.

Protein degrader ADCs using molecular glues and PROTAC payloads offer new therapeutic approaches and are under development

at Baylink.

Addressing
Key Challenges

Baylink tackles critical issues: improving therapeutic index, expanding payload diversity, and overcoming resistance.

This drives the next wave

of precision ADCs.

News

Get the latest updates from us

Baylink Biosciences to Present Its Novel Linker and Payload Technologies at 3rd ADC Linker & Conjugation Summit

PALO ALTO, CA, UNITED STATES, August 13, 2025 -- Baylink Biosciences, a biotechnology ...

Dec 5, 2025

142

Baylink Presents New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

PALO ALTO, Calif., April 25, 2025 -- Baylink Biosciences presented data from its Antibody Drug Conjugate portfolio ...

Apr 25, 2025

529

Baylink To Highlight New Preclinical Data At The American Association For Cancer Research (AACR) Annual Meeting

PALO ALTO, Calif., April 15, 2025 -- Baylink Biosciences today announced that new preclinical data from its portfolio will be presented at ...

Apr 15, 2025

356

All articles